AstraZeneca, the British drugmaker working on one of the world’s leading Covid-19 vaccine candidates, beat third-quarter sales estimates and reiterated it expects data from late-stage trials of the vaccine later this year.

The company has taken on the development of Oxford University’s potential Covid-19 vaccine, scoring billions in funding and signing multiple deals to supply over three billion doses to countries around the world.

Data in October showed the vaccine produces an immune response in both old and young adults. AstraZeneca is expected to publish eagerly awaited late-stage clinical trial data in the coming weeks, according to Reuters.

Expectations are that Britain could start rolling out a successful vaccine in late December or early 2021.